Moderna's Cancer Vaccine Shows Promising Results in Trial with Merck's Keytruda

The combination treatment for head and neck cancer demonstrated positive immune responses and disease control in a small trial.

Moderna and Merck's trial on a cancer vaccine and Keytruda combination reported positive outcomes in patients with head and neck cancers.
The study involved 22 patients and showed preliminary positive clinical responses, including two complete responses.
Moderna's stock rose 6.2%, becoming the biggest gainer on the S&P 500 following the announcement.
The treatment was found to be safe and well-tolerated, with the most common side effects being mild to moderate.
Moderna is expanding its pipeline with 45 products in development, including vaccines for COVID-19, RSV, and norovirus.